The European Medicines Agency (EMA) has recommended a conditional marketing authorisation in the European Union (EU) for teclistamab for the treatment of adult patients with relapsed and refractory myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose cancer has worsened since receiving the last treatment.
According to a new study published in Blood Advances, caregivers for patients with myeloma may suffer from higher rates of anxiety and depression than patients themselves. While medical professionals have long acknowledged the toll a serious or terminal diagnosis can have on a person’s mental health, few studies have investigated how these conditions affect the family members, friends, and loved ones who care for these individuals.
MPE will hold a focus group to find out more about CAR-T from a patient perspective. We will be asking questions that relate to quality of life measurement within CAR-T clinical trials and to the wider impact of CAR-T on individuals and their partners, family members, carers, or friends.
European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has adopted a positive opinion recommending marketing authorization approval (MAA) of melphalan flufenamide, also called melflufen, a drug commercialised by Oncopeptides with the name of Pepaxti®.
The European Hematology Association’s (EHA) annual congress, one of the most important haematology congresses here in Europe, was held in Vienna, Austria from 9 June to 12 June 2022 in a hybrid format.
Myeloma Patients Europe (MPE) attended EHA 2022 in person and interviewed relevant myeloma and AL amyloidosis specialists to provide an overview of the key highlights in both diseases presented during this meeting.
The European Commission has granted conditional approval to CAR-T cell therapy Carvytki (cilta-cel) for the treatment of relapsed and refractory myeloma.
Myeloma Patients Europe (MPE) is pleased to announce that Denis Henrard, an experienced manager in the healthcare sector, has been appointed Chief Executive Officer (CEO). This follows last year’s news that the founding CEO of MPE, Ananda Plate, stood down from the role after ten very successful years.
Myeloma Patients Europe (MPE) held its Annual General Meeting (AGM) on 29 March 2022, where MPE members were invited to discuss present and future MPE projects, vote on the annual budget, and hold board elections. Five members of the current board stepped down either due to reaching the maximum number of terms or for personal reasons: Hans Scheurer, Johannes Brenner and Kristina Modic (first elected in 2016) and Roman Slomkowski (2018) and Nikita E.Shklovskiy-Kordi (2020)
MPE wants to deeply thank these members for their work and commitment during their time of service and their contribution to improving myeloma and AL amyloidosis patients’ lives. Continue reading
A multi-stakeholder coalition consisting of more than 60 representatives from the global patient advocacy and clinical community has formed the International COVID-19 Blood Cancer Coalition (ICBCC) to address the specific impact of the pandemic on immunocompromised blood cancer patients and to recommend solutions and actions to mitigate those risks.
Myeloma Patients Europe (MPE) is here to support Ukrainian patients during this ongoing crisis. If you are a myeloma or AL amyloidosis patient in Ukraine or a refugee in another European country and in need of information on how to access treatment and support, please contact us at email@example.com. Continue reading